Question 1

What does vVARDIS do?

Accepted Answer

vVARDIS develops and commercializes Curodont®, which is the first clinically validated treatment for early-stage cavities that helps preserve the natural tooth structure. Rather than drilling, Curodont® uses proprietary peptide technology to enable the restoration of enamel crystal density throughout the lesion, in a similar way to how nature built the tooth, in a drill-free, needle-free procedure that requires no anesthesia.

Question 2

What is the market opportunity?

Accepted Answer

Tooth decay affects approximately 2.5 billion people globally, according to the World Health Organization. In the United States, we estimate there are approximately 1 billion early-stage cavities, representing a total addressable market for Curodont® of approximately $29 billion. Our serviceable addressable market, the cavities among patients who visit a dentist at least once a year and whose cavities are currently identified and clinically managed, comprises at least 450 million treatable early-stage cavities, a market opportunity of at least $13 billion. We estimate that increasing adoption of AI-powered cavity detection could expand our market opportunity by more than 30%.

Question 3

What is vVARDIS's go-to-market strategy?

Accepted Answer

We use a hybrid model combining our specialized direct sales force, which engages directly with dental practices and dental support organizations (DSOs), with the sales and distribution platform of Henry Schein, our exclusive distributor in the United States and the United Kingdom.

Question 4

How does vVARDIS intend to use the proceeds of its IPO?

Accepted Answer

We intend to use the net proceeds for general corporate purposes, including working capital, operating expenses and capital expenditures, and may also use a portion for acquisitions of, or strategic investments in, complementary businesses, products, services or technologies. Please refer to "Use of Proceeds" in our prospectus.

Question 5

Where is vVARDIS incorporated?

Accepted Answer

vVARDIS Holding AG is a Swiss stock corporation (Aktiengesellschaft) incorporated on November 11, 2020 and registered in the commercial register of the Canton of Zug, Switzerland (CHE-304.163.134). Our registered office is at Gubelstrasse 24, 6300 Zug, Switzerland. Our main U.S. subsidiary is vVARDIS Inc., 99 Wall Street, Suite 1836, New York, NY 10005.

Question 6

Who is vVARDIS's independent registered public accounting firm?

Accepted Answer

Deloitte AG.

Investor FAQs

About the company

Stock Information

Contact Us

Quick Links

About the company

Stock Information

Contact Us

Quick Links

Email Alerts